CAMBRIDGE, United Kingdom, March 04, 2025 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease ...
Mestag Therapeutics, a leading biotech company specialising in fibroblast immunology for inflammatory disease and cancer, has appointed Dr Matthew Sleeman as chief scientific officer. With over 20 ...
CAMBRIDGE, United Kingdom, March 04, 2025 (GLOBE NEWSWIRE) -- Mestag Therapeutics ("Mestag"), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results